BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15462267)

  • 1. Factor V Leiden: association with venous thromboembolism in pregnancy and screening issues.
    Harvey D; Lowe GM
    Br J Biomed Sci; 2004; 61(3):157-64. PubMed ID: 15462267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor V and thrombotic disease: description of a janus-faced protein.
    Nicolaes GA; Dahlbäck B
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):530-8. PubMed ID: 11950687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor V Leiden: a disorder of factor V anticoagulant function.
    Castoldi E; Rosing J
    Curr Opin Hematol; 2004 May; 11(3):176-81. PubMed ID: 15257017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
    Price DT; Ridker PM
    Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B
    Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation factor V and thrombophilia: background and mechanisms.
    Segers K; Dahlbäck B; Nicolaes GA
    Thromb Haemost; 2007 Sep; 98(3):530-42. PubMed ID: 17849041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor V Leiden and activated protein C resistance.
    Segers O; Castoldi E
    Adv Clin Chem; 2009; 49():121-57. PubMed ID: 19947358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
    De Stefano V; Leone G
    Haematologica; 1995; 80(4):344-56. PubMed ID: 7590506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G; Nicolaes GA; Rosing J
    Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
    Strandberg K; Svensson PJ; Ohlin AK
    Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to activated protein C--frequent etiologic factor for venous thrombosis.
    Simkova M; Simko F; Kovacs L
    Bratisl Lek Listy; 2001; 102(5):240-7. PubMed ID: 11725376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism.
    Margaglione M; Brancaccio V; De Lucia D; Martinelli I; Ciampa A; Grandone E; Di Minno G
    Chest; 2000 Nov; 118(5):1405-11. PubMed ID: 11083693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
    Dahlbäck B
    Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders.
    Dahlbäck B
    Int J Lab Hematol; 2016 May; 38 Suppl 1():4-11. PubMed ID: 27161771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential.
    Zotz RB; Gerhardt A; Kluft C; Scharf RE
    Thromb Haemost; 2005 Feb; 93(2):306-10. PubMed ID: 15711747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel mutation (g2172-->c) in the factor V gene in a Chinese family with hereditary activated protein C resistance.
    Cai H; Hua B; Fan L; Wang Q; Wang S; Zhao Y
    Thromb Res; 2010 Jun; 125(6):545-8. PubMed ID: 20304467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor V R506Q mutation-Leiden: an independent risk factor for venous thrombosis but not coronary artery disease.
    Irani-Hakime N; Tamim H; Elias G; Choueiry S; Kreidy R; Daccache JL; Almawi WY
    J Thromb Thrombolysis; 2001 Apr; 11(2):111-6. PubMed ID: 11406725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.